A generic drug for the treatment of neuroendocrine tumors, Myrelez 120 g, has been out of stock in pharmacies for at least seven days. This is according to patients with metastatic cancer who use this drug to make the tumor as inactive as possible.
The supply problems of this drug will last until May and the cause is due to an increase in demand above what the company can supply due to its launch throughout the European Union. Patients residing in Madrid have denounced the problem and have verified the lack of supply in pharmacies.